Targets › DYRK1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on DYRK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas | Cirtuvivint (SM08502) CLK1-4 and DYRK1-4 kinase inhibitor | CLK1, CLK2, CLK3, CLK4, DYRK1 | Phase 2 | Soft Tissue Sarcoma (STS) | Apr 2027 |
Soft Tissue Sarcoma (STS) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.